Journal article
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Abstract
BACKGROUND: Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor-positive early breast cancer in postmenopausal women. Extending treatment with an aromatase inhibitor to 10 years may further reduce the risk of breast-cancer recurrence.
METHODS: We conducted a double-blind, placebo-controlled trial to assess the effect of the extended use of letrozole …
Authors
Goss PE; Ingle JN; Pritchard KI; Robert NJ; Muss H; Gralow J; Gelmon K; Whelan T; Strasser-Weippl K; Rubin S
Journal
New England Journal of Medicine, Vol. 375, No. 3, pp. 209–219
Publisher
Massachusetts Medical Society
Publication Date
July 21, 2016
DOI
10.1056/nejmoa1604700
ISSN
0028-4793